NEOG vs. CLDX, NTLA, MYGN, VIVO, XRAY, MMSI, HAE, QDEL, ICUI, and STAA
Should you be buying Neogen stock or one of its competitors? The main competitors of Neogen include Celldex Therapeutics (CLDX), Intellia Therapeutics (NTLA), Myriad Genetics (MYGN), Meridian Bioscience (VIVO), DENTSPLY SIRONA (XRAY), Merit Medical Systems (MMSI), Haemonetics (HAE), QuidelOrtho (QDEL), ICU Medical (ICUI), and STAAR Surgical (STAA). These companies are all part of the "medical" sector.
Neogen (NASDAQ:NEOG) and Celldex Therapeutics (NASDAQ:CLDX) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, community ranking, profitability and risk.
Celldex Therapeutics received 271 more outperform votes than Neogen when rated by MarketBeat users. Likewise, 74.94% of users gave Celldex Therapeutics an outperform vote while only 57.19% of users gave Neogen an outperform vote.
Neogen has a net margin of 0.17% compared to Celldex Therapeutics' net margin of -2,385.57%. Neogen's return on equity of 3.35% beat Celldex Therapeutics' return on equity.
Neogen has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500.
In the previous week, Celldex Therapeutics had 10 more articles in the media than Neogen. MarketBeat recorded 17 mentions for Celldex Therapeutics and 7 mentions for Neogen. Neogen's average media sentiment score of 0.77 beat Celldex Therapeutics' score of 0.34 indicating that Neogen is being referred to more favorably in the media.
96.7% of Neogen shares are held by institutional investors. 0.7% of Neogen shares are held by company insiders. Comparatively, 3.8% of Celldex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Neogen currently has a consensus price target of $22.50, suggesting a potential upside of 39.66%. Celldex Therapeutics has a consensus price target of $66.00, suggesting a potential upside of 87.07%. Given Celldex Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Celldex Therapeutics is more favorable than Neogen.
Neogen has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Neogen, indicating that it is currently the more affordable of the two stocks.
Summary
Neogen and Celldex Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get Neogen News Delivered to You Automatically
Sign up to receive the latest news and ratings for NEOG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NEOG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
